Practice

Study: Gender, Internet Habits Influence Biosimilar Acceptance

February 15th 2021

By Tony Hagen

Patient characteristics are predictive of whether a switch to a biosimilar is likely to be accepted, investigators found.

Study: Biosimilar Use Varies by Type of Institution and Physician Characteristics

February 8th 2021

By Tony Hagen

Article

Physician specialty and practice setting each play a significant role in whether biosimilars are administered vs originators, according to a large, cross-sectional study.

Long-term Observational Study Supports Switch From Infliximab to SB2 in IBD

February 6th 2021

By Deana Ferreri, PhD

Article

A long-term observational study suggests a non-medical switch from infliximab to SB2 is “a feasible option” for patients with inflammatory bowel diseases (IBD).

Investigators Study Risks of Hypertension, Proteinuria With Bevacizumab

January 19th 2021

By Tony Hagen

Article

The study was designed to elucidate incidence of hypertension and proteinuria in patients treated with bevacizumab reference vs biosimilar products.

Swift Uptake for Mvasi Suggests Provider Comfort With Use

January 18th 2021

By Tony Hagen

Article

Investigators looked at the first 9 months of use following the launch of the bevacizumab biosimilar Mvasi to gauge physician comfort with this agent across tumor types.

Infliximab Biosimilar Switching Study Yields Evidence of Safety, Efficacy

January 14th 2021

By Deana Ferreri, PhD

Article

A need for clinical evidence on the efficacy and safety of infliximab switching led the authors to pursue this investigation.

A Review of the Most-Read Biosimilar Stories of 2020: Part 2

December 27th 2020

By Tony Hagen

Article

In part 2 of this year-end feature, we look at the most-read biosimilar stories of the second half of 2020.

A Review of the Most-Read Biosimilar Stories in 2020: Part 1

December 24th 2020

By Tony Hagen

Article

The top stories in biosimilars for 2020 encompassed biosimilar approvals and launches, the coronavirus disease 2019 pandemic, and the FDA's challenge to stay on top of the rapidly changing health care landscape.

Samsung Bioepis Examines European Awareness of Biosimilars

December 19th 2020

By Tony Hagen

Article

In the EU-5 group of countries, biosimilar awareness is poor, hindering uptake of these potentially cost-saving medicines, a white paper states.

Samsung Bioepis Initiates Phase 3 Trial for Denosumab Biosimilar

December 16th 2020

By Tony Hagen

Article

Samsung Bioepis hopes to gain regulatory approval for a denosumab biosimilar referencing Prolia. The trial will focus on women with postmenopausal osteoporosis.